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Abstract
Background: A key challenge in phase I trials is maintaining rapid escalation in order to avoid exposing too many
patients to sub-therapeutic doses, while preserving safety by limiting the frequency of toxic events. Traditional rule-
based designs require temporarily stopping recruitment whilst waiting to see whether enrolled patients develop
toxicity. This can be both inefficient and introduces logistic challenges to recruitment in the clinic. We describe a
novel two-stage dose assignment procedure designed for a phase I clinical trial (STARPAC), where a good
estimation of prior was possible.
Methods: The STARPAC design uses rule-based design until the first patient has a dose limiting toxicity (DLT) and
then switches to a modified CRM, with rules to handle patient recruitment during follow-up of earlier patients.
STARPAC design is compared via simulations with the TITE-CRM and 3 + 3 methods in various toxicity estimate (T1–5),
rate of recruitment (R1–2), and DLT events timing (DT1–4), scenarios using several metrics: accuracy of maximum
tolerated dose (MTD), numbers of DLTs, number of patients enrolled and those missed; duration of trial; and
proportion of patients treated at the therapeutic dose or MTD.
Results: The simulations suggest that STARPAC design performed well in MTD estimation and in treating patients at
the highest possible therapeutic levels. STARPAC and TITE-CRM were comparable in the number of patients required
and DLTs incurred. The 3 + 3 design often had fewer patients and DLTs although this is due to its low escalation rate
leading to poor MTD estimation. For the numbers of declined patients and MTD estimation 3 + 3 is uniformly worse,
with STARPAC being better in those metrics for high toxicity scenarios and TITE-CRM better with low toxicity. In
situations including doses with toxicities both above and below 30%, the STARPAC design outperformed TITE-CRM
with respect to every metric.
Conclusion: When considering doses with toxicities both above and below the target of 30% toxicities, the two-stage
STARPAC dose escalation design provides a more efficient phase I trial design than either the traditional 3 + 3 or the
TITE-CRM design. Trialists should model various designs via simulation to adopt the most efficient design for their
clinical scenario.
Trial registration: Clinical Trials NCT03307148 (11 October 2017).
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Background
Phase I clinical trials are an essential early-stage in-
vestigation in the development of anti-cancer and
other therapeutic drugs. The main goal of these
studies is to identify the appropriate dose for new
drugs or drug combinations for phase II trials, often
called the recommended phase 2 dose (RP2D). These
studies typically involve a small number of patients.
A key principle for dose escalation in phase I trials
is maintaining rapid dose-escalation in order to
avoid exposing too many patients to sub-therapeutic
doses while preserving safety by limiting the fre-
quency of toxic events (dose limiting toxicities or
DLTs). The maximum tolerated dose (MTD) is esti-
mated limiting the probability of a DLT to a particu-
lar level, the target toxicity level (TTL), which is
often set at 30%. Dose escalation methods for phase
I cancer clinical trials fall into two broad classes: the
traditional and often used rule-based, or “up and
down”, designs, which include the traditional 3 + 3
design [1, 2] and its variations; and relatively recent,
model-based designs such as the continual reassess-
ment method (CRM) [3].
The most commonly employed rule-based design is the
3 + 3 design. It sequentially enrols cohorts of three patients;
the first cohort is treated at a starting dose that is consid-
ered to be safe based on extrapolation from animal toxico-
logical data or prior experience in other disease conditions,
and the subsequent cohorts are treated at increasing dose
levels that have been fixed in advance. The 3 + 3 is conser-
vative with respect to the number of toxicities which occur,
because the dose escalation is performed with caution, but
it can potentially lead to a large number of patients needed
to estimate the MTD, especially if the true MTD is located
in the upper range of the doses tested. This method has
been criticized for assigning low, possibly sub-therapeutic,
doses to a high proportion of patients, often only making
use of information given by the last three or six patients en-
rolled; thereby providing an inefficient estimation of the
MTD and inflexibility in that the method is tailored to a
target toxicity level of around 30%.
An alternative to the rule-based methods for finding
the MTD is to use a model-based approach that assumes
there is a monotone relationship between the dose and
the probability of a DLT. The most commonly applied
model-based approach is the CRM and its variants. The
CRM pre-specifies a dose-toxicity curve (DTC) as well
as the TTL. Prior estimates of the probability of a DLT
at each dose level are provided based on clinical experi-
ence. The DTC is updated with accumulating toxicity
data from the trial. New patients are given the MTD de-
rived from the updated DTC.
The CRM method in its original form treated patients
individually with the initial patient dosed at the MTD
suggested by the (possibly inaccurate) prior DTC,
allowed dose escalations of more than one level (dose
skipping), and required a fixed number of patients (usu-
ally around 20). This caused some criticism both on the
grounds of excess toxicity exposure and the length of
the study given toxicity data from previous patients may
take time to occur. Modified designs treat the initial pa-
tient at a low level and do not allow dose-skipping. They
may also treat patients in cohorts of more than one, and
include early stopping rules to limit study duration [4].
Another suggestion to limit toxicity is the escalation
with overdose control method [5].
A further class of models designed to address the issue
of limited information in the early stage of a CRM are
the two-stage designs [6, 7] whereby patients are initially
treated according to some rule-based design with a tran-
sition to the CRM approach often on occurrence of the
first DLT.
Relative performance of the CRM and 3 + 3 method
Both the 3 + 3 and the CRM method with its variants
have advantages and disadvantages depending on the
toxicity profile of the drug, the number of dose levels,
the DLT required, and the accuracy of the prior estimate
of the CRM dose-toxicity curve [8, 9]. Although ruled-
based designs, compared with model-based designs, tend
to have lower probability of finding the true MTD and
to have more patients treated at sub-MTD doses with
potentially less therapeutic value, they are likely to have
fewer toxicities and can, sometimes, require fewer pa-
tients. These four metrics: MTD accuracy, patients
dosed at MTD, low toxicity and economy of patient
numbers are important in comparing the performance
of alternative phase 1 designs. Van Brummelen et al.,
2016 reported that (n = 11) model-based trials were
shorter, requiring fewer patients, incurred a lower per-
centage of DLTs and treated fewer patients at potentially
sub-therapeutic levels compared with (n = 161) rule-
based trials.
Recent (UK) Medical Research Council (MRC) [10],
Committee for Medicinal Products for Human Use
(CHMP), (CHMP 2006) and FDA (FDA 2011) guid-
ance recommends that alternative to the 3 + 3 designs
should be considered. Despite these design modifica-
tions and recommendations, the CRM and its variants
have not been widely adopted with up to 94% of
studies (n = 172) following a rule-based design. (van
Brummelen et al., 2016).
Love (2017) found that the most prominent barriers to
implementation of a model-based design (e.g. CRM)
were lack of suitable training, chief investigators’ prefer-
ence for rule-based designs (e.g., 3 + 3), a mistaken belief
in regulatory preference for rule-based designs and lim-
ited resources for study design before funding especially
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when DLT may occur in a delayed fashion (up to few
weeks after initial administration) or is cumulative after
repeated administration of a drug.
Accrual given incomplete DLT observation
A challenge of using both rule-based and model-based
methods is that a toxicity/DLT may not be observed for
some time after a patient is recruited. In cancer trials it
is common to wish to consider DLT’s observed during
the first cycle of treatment (usually 14–28 days). Even
when using cohorts of three patients at the same dose,
this can result in patients being recruited while previous
patients have only partial follow-up and therefore, with
incomplete toxicity responses. This is particularly a
problem early in a trial when the next patient could be
recruited and require a dose recommendation, when no
previous patients have completed their first cycle to esti-
mate full toxicity. There have been several attempts to
address this both in the context of rule-based and
model-based studies. An alternative rule-based design,
[11], the accelerated titration design, treats one patient
per dose level until a patient experiences a DLT at which
point the traditional 3 + 3 method is employed. Another
rule-based approach, the rolling six design [12], allows
for accrual of two to six patients on the same dose
which is determined by the number of patients currently
enrolled and evaluable, the number experiencing dose-
limiting toxicity (DLT), and the number still at risk of
developing a DLT. Within the CRM context one of the
modifications previously suggested [4] was to recruit pa-
tients in cohorts rather than singly to increase accrual. A
modification to the CRM process was proposed [13]
called the time-to-event continual reassessment method
(TITE-CRM), that allows patients to be entered in a
staggered fashion enrolling new patients while existing
patients have an incomplete observation by incorporat-
ing the time to the event (the event being a DLT) or the
partial follow-up without DLT for each patient. This
method can be an efficient method of allowing the ad-
vantages of a CRM design to be used with partial follow-
up. However, early in the study, unless overdose control
is employed or dose-skipping prevented, this method
can lead to increased DLTs [14].
In this article we propose an alternative to TITE-CRM
(in order to overcome its limitations) for the STARPAC
trial by using a hybrid two-stage dose escalation with an
initial stage of accelerated dose escalation until the oc-
currence of a DLT at which point an amended CRM is
employed. We then compare the STARPAC design pro-
posal with standard 3 + 3 design, and TITE-CRM using
~ 1000 simulations per scenario to evaluate the key met-
rics of these designs: patients required and skipped (pa-
tient burden), DLTs encountered (toxicity), study length
(economy), MTD determination (accuracy), patients
dosed at MTD (therapeutic utility).
Methods
The STARPAC trial
STARPAC is a Phase 1 trial of repurposing all trans-
retinoic acid (ATRA) as a stromal targeting agent for
pancreatic cancer alongside gemcitabine and nab-
Paclitaxel. STARPAC patients have histologically proven
pancreatic ductal adenocarcinoma (PDAC) which is lo-
cally advanced or metastatic disease which is measurable
according to the Response Evaluation Criteria in Solid
Tumours (RECIST v1.1). Pancreatic cancer is the fourth-
highest cancer killer worldwide (~ 310,000 patients), re-
sponsible for 6% of cancer deaths (overall median sur-
vival ~ 3 months). One of the characteristics of
pancreatic cancer is its intense desmoplastic stroma,
which can account for up to 70% of the tumour volume
and actively participates in tumour initiation, progres-
sion, metastases and the response to therapy [15]. The
formation of stroma is driven by pancreatic stellate cells
(PSCs) as they change from a quiescent, vitamin A stor-
ing phenotype to an activated myofibroblast-like cell.
Normalising the tumour stroma by reprogramming PSCs
to their quiescent phenotype by all-trans retinoic acid
(ATRA) [16, 17], and thereby restoring a more physio-
logical secretome, is an attractive approach to be ex-
plored with this trial. The combination of gemcitabine-
nab-Paclitaxel is licenced for treatment of pancreatic
cancer with well-known toxicity profile [18]. ATRA is
also a well-established drug with more than four decades
of clinical experience for other cancers [19–22], and its
analogues, such as 13-cis retinoic acid (13cisRA)) have
been used in context of pancreatic cancer [23–25]. How-
ever, the combination of these three drugs has never
been used in pancreatic cancer, and hence the phase I
clinical trial. The toxicities are well-known and are
hypothesised for the purposed of design to be additive
and non-synergistic based on the knowledge of mode of
action. Therefore, five dose levels were considered, to
ensure that no patients are treated at sup-optimal cyto-
toxic chemotherapy level. Lowest combination of cyto-
toxic chemotherapy was chosen at 80% because that was
median dosing intensity in phase III clinical trial [26].
Hence we have designed the STARPAC trial with five
dose levels, D1-D5, of Gemcitabine, Nab-Paclitaxel
and ATRA identifies the MTD (maximum tolerated
dose, Table 1).
The STARPAC design and rules
We implemented a two-stage dose selection in order to
balance prevention of excessive toxicity with the objective
of maintaining rapid dose escalation when justified as de-
scribed before [27], where rule-based design (Stage 1) was
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used with a switch to a model-based dose escalation algo-
rithm (Stage 2) upon occurrence of the first DLT. The first
three patients are assigned to dose level D2 unless one of
those three patients incurs a DLT when the switch to the
CRM-based Stage 2 will occur. The dose selection design
is implemented using the R programming language with
the CRM component using the bcrm package [28]
(Additional file 1).
Since DLTs usually manifest after two weeks [26],
STARPAC Stage 1 uses two key rules to determine dose
escalation for patients, when no DLT occurs:
 If a patient has received two-weeks of treatment on
the current dose level, the next patient to be re-
cruited will be allocated to the next higher dose
level.
 If no patient has received two-weeks of treatment
on the current dose level, the next patient to be re-
cruited will be dosed on the same dose level.
On occurrence of the first DLT, Stage 2 uses a
CRM model using data from patients who have had
a DLT or more than three weeks on study treatment
without a DLT. The CRM uses Bayesian method-
ology based on a power function dose toxicity curve,
using physician experience to estimate the probabil-
ity of toxicity occurring at each dose level D1-D5 as
10, 15, 20, 25 and 30% respectively [24–26]. We use
the hyperbolic tangent parameter has the suggested
initial lognormal prior distribution with mean zero
and variance 1.342 [29]. As patient toxicity data is
accumulated alongside their assigned doses, this is
input to the modified CRM, which will then recom-
mend a dose level for the next patient employing a
dose-skipping restriction [30].
The study stopping rule was defined when 6 patients
are recruited to the same dose throughout either stage
or when 24 patients are recruited in total. At that point
a CRM analysis will be performed on the data when all
patients have completed their first cycle (28 days). The
final MTD will be defined as the highest dose level of
ATRA and Gemcitabine / Nab-Paclitaxel for which the
CRM estimated probability of a patient experiencing a
DLT is closest to 30%. The design also allows us to
switch from Stage 2 back to Stage 1 in the event that a
possible DLT is later determined not to have been a
DLT.
As a further safety measure, we also ensure that a
maximum of three patients are recruited (on the same
dose) in any two-week period. For example, if first
patient three are recruited by week 4 (on say dose level
D2), and next two patients are recruited in week 5 (on
D3), then if patient 6 arrives in week 5 they can be re-
cruited (on D3) provided there have been no DLTs. We
will allow a third patient in a 2-week period to wait up
to seven days before start of treatment in order for this
condition not to be violated. If more than seven days is
required before a patient becomes eligible then the pa-
tient is not recruited to the trial and is allocated to
standard care.
The STARPAC design assigns first patient to dose
level D2. If no DLT has been observed, next patient
is assigned to either the same dose as the previous
patient, if no patient on that dose has received at
least 2 weeks of treatment; or, the next dose if at least
one patient has already received 2 weeks of treatment
at that dose. However, once a DLT has been ob-
served, the next dose is assigned using a model-based
CRM taking into account all DLTs and all patients
who have had at least 3 weeks of treatment without a
DLT. We use a power function dose toxicity curve
and do not allow dose-skipping – if the dose is to be
increased it will only do so by one level. We will stop
recruitment when 6 patients have recruited to the
same dose or when the 24th patient is recruited.
Once all patients have completed 28 days of follow-
up, the MTD is selected as that with a posterior
probability of a DLT that is closest to the TTL. This
is illustrated in Fig. 1.
Simulations
The properties of the STARPAC design were assessed
with simulation by the R programming language [31]
using the bcrm function (Additional file 1). Hypothetical
data was simulated with plausible various scenarios,
based on clinical experience [18] (Table 2). The STAR-
PAC design was compared to both the TITE-CRM pro-
cedure and the classic 3 + 3 procedure.
Suppositions applied to TITE-CRM
TITE-CRM was applied to the simulations using the
logistic form for the DTC and starting with the first
3 patients at D2 unless a DLT occurs. The titecrm
function of the dfcrm R package [32] was used for
assigning doses to the simulated patients. For the
TITE-CRM procedure the safety measure of a max-
imum of three patients recruited in any two-week
period was also applied.
Table 1 Dose Levels of STARPAC clinical trial
Dose level Gemcitabine Nab-Paclitaxel ATRA
D1 80% 800mg/m2 80% 100mg/m2 33% 15mg/m2
D2 80% 800mg/m2 80% 100mg/m2 66% 30mg/m2
D3 80% 800mg/m2 80% 100mg/m2 100% 45mg/m2
D4 100% 1000mg/m2 80% 100mg/m2 100% 45mg/m2
D5 100% 1000mg/m2 100% 125mg/m2 100% 45mg/m2
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Suppositions for 3 + 3 design
The 3 + 3 method was also applied starting at D2, with
excessive toxicity at a dose leading to dose de-escalation.
If the lower dose has been evaluated before, it is
declared to be the (estimated) MTD. However, if the
lower dose has not been evaluated then three patients
are recruited. If all doses are declared too toxic by 3 + 3,
then no MTD is declared. For the 3 + 3 design,
Fig. 1 Flowchart of STARPAC design
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presenting patients were not recruited if the three pa-
tients currently being treated had not yet provided a tox-
icity result enabling the dose level of the next three
patients to be determined. A toxicity result is available
when the current 3 patients complete their cycle without
any DLTs (at which point the next three can be recruited
at a higher dose level) or with 1 DLT (at which point the
next three can be recruited at the same dose level), or
when a second DLT occurs (at which point the next
three can be recruited at a lower dose level) or if for a
second set of three patients (after a previous single DLT)
when a single DLT occurs (at which point the next three
can be recruited at a lower dose level). Any patients pre-
senting while the next dose level is undetermined are
unable to be recruited.
1000 datasets were simulated using each of the three
designs and for each of the forty (toxicity (T) and DLT
timing (DT)) scenarios using the different patient arrival
rates (R).
These in silico simulations did not require ethical ap-
proval, as no humans or animals were used. STARPAC
study was approved by South Central - Berkshire
Research Ethics Committee (15/SC/0548), but is not part
of the manuscript.
Results
Simulation results
Summary of performance based on simulations for
STARPAC, TITE-CRM and 3 + 3 designs is presented in
terms of: patients required and skipped (not-recruited
due to insufficient information to determine next dosing
level: patient burden), DLTs encountered (toxicity), study
length (economy), MTD determination (accuracy),
patients dosed at MTD (therapeutic utility) in Table 3.
We also report the proportion of times each dose level
is selected as MTD and the proportion of patients
treated at each dose (Additional file 2).
In Table 3 data are summarised for the three de-
signs in each of the five toxicity (T) scenarios.
Values in Table 3 are for DLT timing-scenario DT1.
Results for the study length and the numbers of pa-
tients skipped are presented separately depending on
the recruitment rate. For all other results, the value
in Table 3 is for R1 (one patient per week). Below
each value in Table 3 is the range of that parameter
across the four DLT timing scenarios (DT1-DT4)
and (except for study length and patients skipped)
the two recruitment rates. It is interesting to note
that the ranges are narrow compared to the differ-
ences between designs and toxicity scenarios, sug-
gesting that DLT timing scenarios has limited impact
on any of the designs, an important consideration
for future designs.
Accuracy to determine MTD
The classic, rule-based 3 + 3 design never accurately esti-
mates the correct MTD. For the scenarios including doses
with greater than 30% toxicity (T1 and T2), STARPAC de-
sign is more likely to select the correct MTD than the
other two designs, but all fair poorly. For those with the
maximal dose included to be less than or equal to 30%
(T3 and T4), TITE-CRM is more likely to pick the correct
MTD, than STARPAC design. In these scenarios (T3 and
T4), STARPAC is much more likely to pick the correct
MTD than 3 + 3. We note that the likelihood of identify-
ing the MTD with any of these designs is highly variable
depending on the underlying toxicities of the doses con-
sidered. For example, in scenario T2, the MTD is only
correctly identified less than 20% of the time (even by the
best design). For scenario T4 in which the maximal dose
has toxicity of just 20%, TITE-CRM correctly chooses that
does up to 90% of the time, and STARPAC over 70%. In
the highly variable, non-linear scenario, STARPAC design
outperforms the other two designs.
Toxicity (DLT frequency)
None of the designs has more than average six patients
with DLTs in any of the scenarios studied, and mostly
the mean is 3–4 DLTs per trial. For four of the five tox-
icity rate scenarios, 3 + 3 has the fewest patients and the
fewest DLTs, but, as noted, it is also least likely to select
the target dose. We must note that a design that stops
after treating three patients at the lowest dose will
always recruit the fewest and have the fewest DLTs, but
it does not help one find the MTD. TITE-CRM design
has the most DLTs in all scenario compared to other de-
sign, except for T4 scenario where STARPAC design
fairs poorly.
Table 2 Scenarios for simulation
Toxicity
scenario
Type of scenario Dose Levels
D1 D2 D3 D4 D5
T1 Linear, very high 10 20 30 40 50
T2 Linear, high 10 20 25 30 40
T3 Linear, anticipated 10 15 20 25 30
T4 Linear, low 5 10 12 15 20
T5 Non-linear, variable 5 15 30 50 70
1. Rates of recruitment scenarios (R): patients recruited randomly, with two
(Poisson process) arrival rates considered:
a. R1: routine average arrival 1 patient per week and
b. R2: accelerated average arrival rate 1.5 patients per week.
2 Toxicity occurrence scenarios (T)
3. The DLT times (for those with a DLT) were simulated using 4 timing
(DT) scenarios:
a. DT1: uniformly between 8 and 21 days after recruitment: most plausible
based on clinical experience [16]
b. DT2: uniformly between 11 and 28 days after recruitment
c. DT3: at either 11 or 21 days with probabilities of 25 and 75%
d. DT4: at either 11 or 21 days with probabilities 30 and 70%.
Bold typeface signifies acceptable DLT to declare MTD.
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Patients required and study length (economy)
The ordering of designs in terms of the number of pa-
tients recruited is always the same as for the frequency
of DLTs within the trial. On the other hand, the rule-
based 3 + 3 design most often is longest in study length,
but requires least patients except for scenario T4 where
it requires more patients than TITE-CRM (but fewer
than STARPAC design). TITE-CRM requires more pa-
tients than STARPAC design for scenarios T1, T2 and
T5, whereas STARPAC requires more for T4 (and there
is little to choose between the designs for T3).
Skipped patients (patient and investigator burden)
For the numbers of skipped patients 3 + 3 is uniformly
(and substantially) worse than the other designs. STAR-
PAC is best in scenarios T1, T2 and T5; whereas TITE-
CRM is best for T4; and the two designs are very similar
for T3. The order of designs in terms of the study dur-
ation is always the same as for patients skipped – the
more patients are skipped the longer the trial.
Discussion
It has been noted that phase 1 trials often have a correct
MTD estimation rate of only around 40% due to the low
sample size [33]. We have described an alternative two
stage dose-escalation (STARPAC) adaptive design [30] for
phase 1 trials with delayed toxicity estimation (up to 28
days). We compare STARPAC design with TITE-CRM
and 3 + 3 designs via simulation with the R programming
language to illustrate the utility of simulation-based as-
sessment under various plausible clinical scenarios, to en-
able evidenced based judgement dependent on key
metrics which may relevant for the disease and patient
population. An illustration of comparison is shown in Fig.
2. Our design compares favourably to other recently de-
scribed modifications of TITE-CRM [34–37], such that re-
cruitment is quicker and application of the design is
easier. Furthermore, we have applied this design after
rigorous simulations on to an actual oncology clinical trial,
whilst others have yet to find real-life application.
Our simulations suggest that accuracy depends critic-
ally on the real toxicities of the doses studied, an
Table 3 Results of simulations
Design toxicity patients DLTs study length
(1.0/wk)
number skipped
(1.0/wk)
study length
(1.5/wk)
number skipped
(1.5/wk)
MTD
STARPAC T1 12.2
(12.2, 12.7)
3.28
(3.20, 3.54)
15.8
(15.8, 16.1)
3.47
(3.47, 3.76)
13.2
(13.0, 13.6)
7.32
(7.32, 7.67)
0.342
(0.317, 0.363)
TITE-CRM T1 14.5
(14.5, 15.3)
4.23
(4.23, 4.66)
19.1
(19.1, 19.9)
4.27
(4.27, 4.57)
16.2
(15.9, 16.3)
9.07
(9.07, 9.41)
0.217
(0.162, 0.217)
3 + 3 T1 10.2
(10.1, 10.4)
2.64
(2.62, 2.71)
20.9
(20.9, 22.2)
9.90
(9.90, 10.28)
17.9
(17.9, 19.0)
14.44
(14.41, 14.95)
0.234
(0.234, 0.260)
STARPAC T2 12.5
(12.4, 13.2)
3.01
(2.97, 3.30)
16.2
(16.2, 16.5)
3.70
(3.67, 3.75)
13.2
(13.2, 14.1)
7.57
(7.50, 8.09)
0.163
(0.117, 0.174)
TITE-CRM T2 14.0
(13.8, 14.3)
3.66
(3.59, 3.81)
18.3
(17.9, 18.3)
4.15
(4.04, 4.15)
15.4
(14.9, 15.4)
8.90
(8.43, 8.95)
0.118
(0.070, 0.118)
3 + 3 T2 11.1
(11.1, 11.1)
2.59
(2.59, 2.63)
23.2
(23.2, 24.2)
10.95
(10.95, 11.17)
19.7
(19.7, 20.7)
16.05
(16.05, 16.31)
0.127
(0.127, 0.144)
STARPAC T3 13.2
(13.0, 13.7)
2.74
(2.68, 2.90)
17.1
(17.1, 17.4)
3.86
(3.82, 4.11)
13.9
(13.9, 14.8)
7.87
(7.87, 8.38)
0.468
(0.441, 0.506)
TITE-CRM T3 13.0
(12.7, 13.2)
2.88
(2.85, 3.02)
17.0
(16.3, 17.0)
3.87
(3.71, 3.87)
14.0
(13.7, 14.1)
8.00
(7.90, 8.12)
0.637
(0.637, 0.708)
3 + 3 T3 11.9
(11.9, 12.2)
2.39
(2.39, 2.43)
25.3
(25.3, 27.1)
12.18
(12.18, 12.67)
21.6
(21.6, 23.2)
17.93
(17.93, 18.75)
0.165
(0.141, 0.168)
STARPAC T4 15.0
(14.7, 15.6)
2.23
(2.16, 2.37)
19.5
(19.4, 19.7)
4.60
(4.58, 4.64)
15.8
(15.8, 16.8)
8.90
(8.90, 9.69)
0.728
(0.691, 0.776)
TITE-CRM T4 11.4
(10.9, 11.6)
1.71
(1.63, 1.82)
14.6
(14.6, 15.0)
3.32
(3.19, 3.40)
12.3
(11.8, 12.5)
7.04
(6.59, 7.04)
0.895
(0.879, 0.932)
3 + 3 T4 13.2
(13.2, 13.4)
1.79
(1.78, 1.82)
29.2
(29.2, 29.9)
14.12
(14.12, 14.84)
24.9
(24.9, 25.7)
20.81
(20.81, 21.85)
0.456
(0.443, 0.473)
STARPAC T5 12.8
(12.7, 13.3)
3.59
(3.54, 3.81)
16.5
(16.4, 17.0)
3.74
(3.74, 3.88)
13.7
(13.6, 14.2)
7.41
(7.41, 8.08)
0.444
(0.439, 0.476)
TITE-CRM T5 16.6
(16.5, 17.0)
5.11
(5.11, 5.51)
21.6
(21.5, 22.3)
5.08
(4.92, 5.17)
18.2
(17.9, 18.6)
10.66
(10.44, 10.72)
0.347
(0.255, 0.347)
3 + 3 T5 9.9
(9.9, 10.1)
2.65
(2.65, 2.68)
20.4
(20.4, 21.7)
9.55
(9.55, 9.98)
17.3
(17.3, 18.7)
13.91
(13.91, 14.68)
0.349
(0.332, 0.349)
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important clinical consideration. Nevertheless, we have
seen that in our five scenarios it varied between just over
10% to just under 90%, across the three design models
and multiple scenarios that we have compared.
Conclusions
The STARPAC design has advantages and disadvantages
compared to the alternative TITE-CRM method, and
both methods appear superior to the traditional 3 + 3 de-
sign particularly with regard to correct estimation of the
MTD and duration of the trial. However, whenever the
doses considered for the trial include ones with toxicity
levels both above and below the target (TTL) of 30%,
the new STARPAC design outperforms both 3 + 3 and
TITE-CRM.
There are several reasons suggested for the high failure
rate of confirmatory phase 3 trials. One reason may be a
suboptimal treatment dose being selected for phase 2
and phase 3 trials. In our simulations the proposed
STARPAC design is nearly always superior to 3 + 3 in
terms of the accuracy of MTD estimation and, in studies
that include doses with toxicity levels above 30%, it is
superior to TITE-CRM as well.
We encourage clinical trialists to use simulations to
provide evidence based adoption of different design
models with particular reference to disease condition
and patient population being studied.
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